Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in pediatric and young adult ALK+ ALCL, IMT, and solid tumors
NCT04925609Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Aug 2022
- Primary completion
- Dec 2033
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of brigatinib in Anaplastic Large Cell Lymphoma ALK-positive, inflammatory myofibroblastic tumor (IMT), solid tumor, sponsored by Princess Máxima Center for Pediatric Oncology. Started Aug 2022; status: recruiting.
02
Drugs
brigatinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positiveinflammatory myofibroblastic tumor (IMT)solid tumor
Beyond the preview
Go deeper on NCT04925609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925609.